Inflammatory effects of autologous, genetically modified autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.

This research compared the effects of injecting different types of mesenchymal stem cells (MSCs) – specifically autologous (from the same individual), genetically modified autologous, allogeneic (from a different individual of the same species), and xenogeneic (from a different species) – into horse joints. They found that the inflammation response was greater when using allogeneic and xenogeneic MSCs, and suggest further research into the therapeutic potential of genetically engineered MSCs.

Research Design and Methodology

• The subjects of this study were six Thoroughbred mares (female horses), all five years old. The selection of a single breed and age group helped to establish a controlled environment, minimizing potential age or breed-specific variations.
• The researchers injected one fetlock joint (a joint located in the horse’s leg) with Gey’s balanced salt solution as a control measure, to compare the effects of the different stem cell types.
• Different categories of MSCs were injected into each horse’s fetlock joint, and the horses were monitored for 28 days for various clinical and inflammatory parameters, which provide indicators of inflammation, swelling, and pain in the joint.

Study Findings

• As per the results, no significant differences were observed between the effects of autologous and genetically modified autologous MSCs, suggesting that the genetic modification didn’t notably alter the cells’ impact on inflammation or swelling.
• Allogeneic and xenogeneic MSCs produced an noticeably increased inflammatory response 24 hours after injection compared to either autologous MSC group.
• Gene products were also detected up to two days post-injection in the joints where genetically engineered MSCs were used, indicating that these can be used to deliver gene products to a targeted area.

Conclusions and Implications

• The researchers concluded that genetically engineered MSCs show promise as a means of delivering gene products to targeted areas. If they can effectively reduce inflammation and pain, they may offer a potential therapy for conditions affecting the joints.
• However, this study found that using allogeneic and xenogeneic MSCs induced a greater inflammatory response, which has implications for their use in clinical practice. Strategies to manage this response would be necessary to minimize potential adverse effects.